SAN DIEGO — A novel tool for educating patients with inflammatory bowel disease on biologic therapies failed to improve upon standard education with regard to shared decision-making, according to data presented at Digestive Diseases Week.
“For patients with moderate-to-severe IBD, there are multiple biologics that could be used to treat their condition,” Christopher Velasquez Almario, MD, of Cedars-Sinai Medical Center, told Healio. “However, the biologic options are all different in how they work, how they are given, and their side-effect profile.”
Almario noted